These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

312 related items for PubMed ID: 16276350

  • 1. Bone mineral density changes on androgen deprivation therapy for prostate cancer and response to antiresorptive therapy.
    Yaturu S, DjeDjos S, Alferos G, Deprisco C.
    Prostate Cancer Prostatic Dis; 2006; 9(1):35-8. PubMed ID: 16276350
    [Abstract] [Full Text] [Related]

  • 2. Effects of alendronate on bone mineral density in men with prostate cancer treated with androgen deprivation therapy.
    Bruder JM, Ma JZ, Wing N, Basler J, Katselnik D.
    J Clin Densitom; 2006; 9(4):431-7. PubMed ID: 17097529
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Zoledronic acid initiated during the first year of androgen deprivation therapy increases bone mineral density in patients with prostate cancer.
    Ryan CW, Huo D, Demers LM, Beer TM, Lacerna LV.
    J Urol; 2006 Sep; 176(3):972-8; discussion 978. PubMed ID: 16890673
    [Abstract] [Full Text] [Related]

  • 5. Androgen deprivation in men with prostate cancer is associated with an increased rate of bone loss.
    Preston DM, Torréns JI, Harding P, Howard RS, Duncan WE, McLeod DG.
    Prostate Cancer Prostatic Dis; 2002 Sep; 5(4):304-10. PubMed ID: 12627216
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Suppression of bone density loss and bone turnover in patients with hormone-sensitive prostate cancer and receiving zoledronic acid.
    Ryan CW, Huo D, Bylow K, Demers LM, Stadler WM, Henderson TO, Vogelzang NJ.
    BJU Int; 2007 Jul; 100(1):70-5. PubMed ID: 17552955
    [Abstract] [Full Text] [Related]

  • 8. The role of bisphosphonates in men with prostate cancer receiving androgen deprivation therapy.
    Smith MR.
    Oncology (Williston Park); 2004 May; 18(5 Suppl 3):21-5. PubMed ID: 15202584
    [Abstract] [Full Text] [Related]

  • 9. Comparative study of the protective effect of different intravenous bisphosphonates on the decrease in bone mineral density in patients submitted to radical prostatectomy undergoing androgen deprivation therapy. A prospective open-label controlled study.
    Rodrigues P, Hering FO, Bruna P, Meller A, Afonso Y.
    Int J Urol; 2007 Apr; 14(4):317-20. PubMed ID: 17470161
    [Abstract] [Full Text] [Related]

  • 10. Long-term changes in bone mineral density and predicted fracture risk in patients receiving androgen-deprivation therapy for prostate cancer, with stratification of treatment based on presenting values.
    Wadhwa VK, Weston R, Mistry R, Parr NJ.
    BJU Int; 2009 Sep; 104(6):800-5. PubMed ID: 19338564
    [Abstract] [Full Text] [Related]

  • 11. Osteoporosis in men treated with androgen deprivation therapy for prostate cancer.
    Ross RW, Small EJ.
    J Urol; 2002 May; 167(5):1952-6. PubMed ID: 11956415
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Bone mineral density changes in patients with prostate cancer during the first 2 years of androgen suppression.
    Morote J, Orsola A, Abascal JM, Planas J, Trilla E, Raventos CX, Cecchini L, Encabo G, Reventos J.
    J Urol; 2006 May; 175(5):1679-83; discussion 1683. PubMed ID: 16600728
    [Abstract] [Full Text] [Related]

  • 15. Pamidronate to prevent bone loss during androgen-deprivation therapy for prostate cancer.
    Smith MR, McGovern FJ, Zietman AL, Fallon MA, Hayden DL, Schoenfeld DA, Kantoff PW, Finkelstein JS.
    N Engl J Med; 2001 Sep 27; 345(13):948-55. PubMed ID: 11575286
    [Abstract] [Full Text] [Related]

  • 16. Risedronate recovers bone loss in patients with prostate cancer undergoing androgen-deprivation therapy.
    Izumi K, Mizokami A, Sugimoto K, Narimoto K, Miwa S, Maeda Y, Kadono Y, Takashima M, Koh E, Namiki M.
    Urology; 2009 Jun 27; 73(6):1342-6. PubMed ID: 19371939
    [Abstract] [Full Text] [Related]

  • 17. Health care cost associated with prostate cancer, androgen deprivation therapy and bone complications.
    Krupski TL, Foley KA, Baser O, Long S, Macarios D, Litwin MS.
    J Urol; 2007 Oct 27; 178(4 Pt 1):1423-8. PubMed ID: 17706711
    [Abstract] [Full Text] [Related]

  • 18. Intravenous zoledronic acid to prevent osteoporosis in a veteran population with multiple risk factors for bone loss on androgen deprivation therapy.
    Bhoopalam N, Campbell SC, Moritz T, Broderick WR, Iyer P, Arcenas AG, Van Veldhuizen PJ, Friedman N, Reda D, Warren S, Garewal H.
    J Urol; 2009 Nov 27; 182(5):2257-64. PubMed ID: 19758618
    [Abstract] [Full Text] [Related]

  • 19. Changes in bone mineral density in patients with prostate cancer treated with androgen deprivation therapy.
    Bernat MM, Pasini J, Mareković Z.
    Coll Antropol; 2005 Dec 27; 29(2):589-91. PubMed ID: 16417166
    [Abstract] [Full Text] [Related]

  • 20. Androgen deprivation in veterans with prostate cancer: implications for skeletal health.
    Wilcox A, Carnes ML, Moon TD, Tobias R, Baade H, Stamos E, Elliott ME.
    Ann Pharmacother; 2006 Dec 27; 40(12):2107-14. PubMed ID: 17132807
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 16.